Taranabant Loss No Surprise For Obesity Field, But Shock To Merck’s Pipeline

Merck's widely expected decision to drop its Phase III obesity candidate taranabant places further doubt on the tainted cannabinoid-1 receptor antagonist class, but it also places doubt on Merck's near-term pipeline